Articles On Starpharma Holdings (ASX:SPL)
Title | Source | Codes | Date |
---|---|---|---|
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | SPL | 1 day ago |
Which ASX companies are resurrecting abandoned drugs? Part 3
Several ASX companies are repurposing or resurrecting abandoned or under utilised drugs Paradigm Biopharmaceuticals identified the potential of FDA-approved PPS that has a long track record of treating inflammation Starpharma has develope... |
Stockhead | SPL | 1 week ago |
Starpharma partners with UK investment firm to create Petalion Therapeutics
Australian company Starpharma (ASX:SPL) has announced a strategic partnership with Medicxi to co-found a new UK-based company called Petalion Therapeutics. |
BiotechDispatch | SPL | 2 weeks ago |
Closing Bell: Gains in Gold and Tech stocks offset by losses in Energy as oil price retreats
The ASX200 closed up slightly by +0.1% on Monday as gains in tech and gold stocks were offset by losses in the energy sector. Energy stocks struggled as crude prices fell more than US$1 a barrel in Asian hours today after Israel confirmed... |
Stockhead | SPL | 2 weeks ago |
Starpharma and Medicxi partner to create UK-based oncology company called Petalion Therapeutics
Australian biotech Starpharma Holdings (ASX: SPL) has entered into a strategic partnership with UK life sciences investment firm Medicxi to establish a UK-based company known as Petalion Therapeutics. Petalion will initially focus on develo... |
smallcapsau.mystagingwebsite.com | SPL | 2 weeks ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | SPL | 1 month ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | SPL | 1 month ago |
ASX Health Stocks: Starpharma suffers setback as FDA rejects appeal, shares down 10pc
Starpharma suffers setback after US FDA appeal rejected LTR Pharma to commence study on erectile dysfunction nasal spray, SPONTAN Starpharma suffers FDA setback Starpharma (ASX:SPL) fell -10% this morning after announcing a negative out... |
Stockhead | SPL | 2 months ago |
In Case You Missed It: A gold scoping study and high-grade copper lead the way
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today. ICYMI Leade... |
Stockhead | SPL | 5 months ago |
3 ASX healthcare shares up 10% to 22% on news
There have been some big movers in the healthcare sector on Wednesday. Here's why these ASX healthcare shares are up over 10% today: Mayne Pharma Group Ltd (ASX: MYX) The Mayne Pharma share price is up over 13% to $3.12. Investors have be... |
Motley Fool | SPL | 6 months ago |
Starpharma announces the presentation of DEP irinotecan combination data
Starpharma (ASX:SPL) has announced the presentation of data that it says demonstrate the benefits of combining its DEP irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in model... |
BiotechDispatch | SPL | 6 months ago |
ASX Health Stocks: Starpharma full steam ahead on VIRALEZE study, Dimerix to use QYTOVRA as brand name
Dimerix’s drug granted QYTOVRA as brand name by US FDA Starpharma completes recruitment for VIRALEZE study in UK Invion adds South Korea to list of exclusive territories for Photosoft FDA says QYTOVRA can be used as DMX-200 brand name... |
Stockhead | SPL | 7 months ago |
Starpharma Holdings (ASX:SPL) – Webinar Presentation
Dr Jackie Fairley – CEO – Starpharma Holdings (ASX:SPL) is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications. |
ShareCafe | SPL | 7 months ago |
Jobs data points to rate rise
After a stronger-than-expected US inflation figure for August, the Australian August job report blew expectations out of the water, with 64,900 jobs created in the month, well above the 23,000 anticipated by economists. The unemployment rat... |
Rask Media | SPL | 7 months ago |
S&P/ASX 200 (INDEXASX: XJO) trades lower ahead of US inflation print
A tech slide dragged the ASX indices lower on Wednesday, ahead of the US inflation data coming in overnight. Consensus expectations were for the US headline consumer price index (CPI) to show core inflation at 3.6% for the year to August, u... |
Rask Media | SPL | 7 months ago |
Investors boost Starpharma in response to interim data from clinical trial
Australian company Starpharma (ASX:SPL) has announced it will present positive interim data from the trial of its DEP irinotecan at a key international oncology conference in October in the US. |
BiotechDispatch | SPL | 7 months ago |
Closing Bell: Tempus Trap, ASX200 loses its bottle, James Bay makes more hay on 2nd day
ASX 200 falls sharply from the open, tracking Wall St sell off ahead of US CPI read tonight Most sectors decline led by Tech and Industrials Tempus Resources jumps 50%, cops a speeding ticket Australian shares stepped off the into th... |
Stockhead | SPL | 7 months ago |
In Case You Missed It: A consumer products divestment and a dash of lithium
Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today. ICYMI Leader... |
Stockhead | SPL | 7 months ago |
Why Delta Lithium, Liontown, Pact, and Starpharma shares are storming higher
It has been a disappointing day for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 0.8% to 7,147 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are... |
Motley Fool | SPL | 7 months ago |
ASX Health Stocks: Starpharma jumps 30pc after cancer drug helps enable ‘100 per cent’ control rate
Starpharm jumps after disclosing interim Phase 1/2 results Chimeric Therapeutics to commence Phase 1b clinical trial Island Pharma gets key patent grant in the US Starpharma jumps after positive Phase 1/2 results Starpharma (ASX:SPL) ju... |
Stockhead | SPL | 7 months ago |
Here's why the Starpharma share price just exploded 50%!
The Starpharma Holdings Ltd (ASX: SPL) share price came rocketing out of the gates this morning. At one stage, the dendrimer products developer's shares were up as much as 58% to 20.5 cents. Starpharma's shares have pulled back a touch sin... |
Motley Fool | SPL | 7 months ago |
Top 10 at 11: Starpharma has excellent drug trial news, Firebrick doesn’t and NIS takes a breather
Stockhead’s Top 10 at shortly-before-11-ish, published surprisingly close to on time, considering I was still shaking the tiles off the roof with my snoring when the market doors opened today. It highlights the best (and sometimes worst) pe... |
Stockhead | SPL | 7 months ago |
ASX August Winners: Everyone lost. August was rough.
The S&P ASX 200 was down 0.73% in August with mid caps and small caps down 1.3% for the month Eight of 11 sectors down in August with consumer discretionary leading winners and utilities the laggards Tech stock 4DS Memory rises more th... |
Stockhead | SPL | 7 months ago |
4 ASX healthcare shares charging higher on positive earnings updates
These four ASX healthcare shares are bucking the trend today with strong share price gains following the release of their latest financial reports. As earnings season continues, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 0.0... |
Motley Fool | SPL | 8 months ago |
Market Highlights: ASX to fall as Big Tech retreats; and here’s how Aussies are being duped by scammers
Local shares to open lower on Monday as US Big Tech retreated Bill Gross says Treasuries are overvalued City Index provides three most common type of scams The ASX is set to open lower by -0.35% on Monday as Wall Street ended mixed in a... |
Stockhead | SPL | 8 months ago |
Closing Bell: Nervy day on ASX ahead of RBA decision; Ecofibre lights up while Silver Lake sinks
The ASX couldn’t make up its mind, a bit like economists looking ahead to the RBA decision tomorrow. Health Care and Industrials Stocks had a day to savour, while Staples and IT largely did not. Some standout small caps: TALi Digital, Ecof... |
Stockhead | SPL | 8 months ago |
Why IGO, Patriot Battery Metals, Silver Lake, and Starpharma shares are sinking today
The S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. In afternoon trade, the benchmark index is down 0.2% to 7,388.3 points. Four ASX shares that are falling more than most today are listed below. Hereâs why... |
Motley Fool | SPL | 8 months ago |
Why is this ASX All Ords share sinking 34% on Monday?
The Starpharma Holdings Ltd (ASX: SPL) share price is ending the month in disastrous fashion. In morning trade, the ASX All Ords biotechnology share is down 34% to a 52-week low of 21.5 cents. Why is this ASX All Ords share being sold off?... |
Motley Fool | SPL | 8 months ago |
Why Legend Mining, Medibank, Starpharma, and Weebit Nano shares are sinking
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) looks set to end its losing streak. At the time of writing, the benchmark index is up 0.5% to 7,116 points. Four ASX shares that have failed to follow the market higher today are li... |
Motley Fool | SPL | 9 months ago |
AZD0466 clinical data presented by AstraZeneca at international congress
Starpharma (ASX:SPL) has announced the recent presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress. |
BiotechDispatch | SPL | 10 months ago |
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak
The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley Throughout history,... |
Stockhead | SPL | 10 months ago |
ASX Health Stocks: Anteris’ 3D heart valve shows consistent results; as Nyrada announces a new lead drug
Anteris’ study is progressing well at the one year and 30-day time points Imugene’s Phase 1 trial has progressed to the next cohort level Nyrada has a new lead drug Regenerative medicine biotech Anteris Technologies (ASX:AVR) has just p... |
Stockhead | SPL | 10 months ago |
Starpharma (ASX:SPL) CEO announces resignation after 16 years
Starpharma’s (ASX:SPL) Chief Executive Officer, Dr Jackie Fairely, resigns after 16 years in the role During her tenure, Dr Fairley “transformed” Starpharma from a startup to a “mature organisation” with multiple commercial partnership... |
themarketherald.com.au | SPL | 10 months ago |
Starpharma announces that Viraleze approved in Malaysia
Starpharma (ASX:SPL) has announced that it has achieved regulatory approval for its antiviral nasal spray product, Viraleze, in Malaysia. |
BiotechDispatch | SPL | 10 months ago |
ASX Health Stocks: OncoSil to commence trial; Korea and Malaysia next stops for these biotechs
OncoSil gets Ethics committee approval Starpharma’s nasal spray VIRALEZE granted approval in Malaysia Botanix Pharmaceuticals strikes deal in Korea Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committe... |
Stockhead | SPL | 10 months ago |
Starpharma’s [ASX:SPL] Viraleze Nasal Spray Receives Approval in Malaysia
Biotech Starpharma has received regulatory approval for its Viraleze product to be used in Malaysia, adding the product to a wider market base that now spans 35 countries as it looks into further COVID-19 studies in the UK. The post Starpha... |
MoneyMorning | SPL | 10 months ago |
Starpharma (ASX:SPL) secures VIRALEZE regulatory approval in Malaysia
Starpharma (SPL) secures regulatory approval for its VIRALEZE antiviral nasal spray in Malaysia The registration of VIRALEZE in Malaysia will allow Starpharma and its commercial partners to market and sell the product throughout the coun... |
themarketherald.com.au | SPL | 10 months ago |
Starpharma announces the appointment of chief financial officer
Starpharma (ASX:SPL) has announced the appointment of Justin Cahill as its chief financial officer and company secretary. |
BiotechDispatch | SPL | 1 year ago |
CLOSING BELL: The ASX engine rooms roar to life, delivering a 1.2% touch worthy of Midas himself
What a solid day it’s been for the ASX today, with the benchmark maintaining a strong run past +1.1% for the afternoon, to finish at +1.18% when the bell finally rang, and the old ladies running the ASX called “pencils down” and everyone go... |
Stockhead | SPL | 1 year ago |
Why AGL, Retail Food Group, Starpharma, and TPG shares are rising today
The S&P/ASX 200 Index (ASX: XJO) has followed Wall Streetâs lead and is on course to end the week in the red. At the time of writing, the benchmark index is down 0.8% to 7,094.3 points. Four ASX shares that have not let that hold th... |
Motley Fool | SPL | 1 year ago |
Starpharma (ASX:SPL) receives $7.1m R&D tax incentive refund
Biopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax incentive refund The tax offset relates to SPL’s Australian and global expenses over the 2022 financial year Starpharma CEO Jackie Fairley... |
themarketherald.com.au | SPL | 1 year ago |
Market Highlights: SBF finds $375m down the back of mum and dad’s couch, and 5 ASX small caps to watch today
After yesterday’s pre-Chrimbo spend-up, SPI Futures are down 66 points (-0.38%) this morning, threatening to wipe out yesterday’s 41-point gain. That’s on the back of some good/bad, depends-on-your-worldview news out of the US that data con... |
Stockhead | SPL | 1 year ago |
Positive preliminary results from trial involving candidate from AZ-Starpharma collaboration
The preliminary results of the clinical trial involving AstraZeneca's AZD0466 and the drug delivery platform developed by Starpharma (ASX:SPL) have been presented at the 2022 American Society of Hematology annual meeting. |
BiotechDispatch | SPL | 1 year ago |
ASX 200 closes in green as utilities & IT gain
Highlights The ASX 200 benchmark index closed in the green today (December 14), gaining 48.00 points, or 0.67%, to end at 7,251.30 points. Over the last five days, the index has gained 0.30%, but is down 2.60% for the last year to date... |
Kalkine Media | SPL | 1 year ago |
Starpharma (ASX:SPL) registers VIRALEZE nasal spray in Indonesia
Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisationThe company says Indonesia represents an “exciting market opportunity” as its the largest and most populated country in Southeast... |
themarketherald.com.au | SPL | 1 year ago |
ASX Health Stocks: Clarity reveals Phase 1 success; Starpharma and Oncosil head for Asia
Clarity Pharma announced positive results from Phase 1 trial Starpharma brings VIRALEZE to Indonesia Race Oncology has a new CEO Clarity Pharma (ASX:CU6) announced that its diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER has met all... |
Stockhead | SPL | 1 year ago |
Why Bendigo Bank, Block, Megaport, and Starpharma shares are rising today
In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.2% to 7,196.9 points. Four ASX shares that are climbing more than most today are listed belo... |
Motley Fool | SPL | 1 year ago |
5 ASX shares trading near 52-week lows that insiders have been buying
Thereâs been plenty of insider buying going on among ASX shares lately, and many of the targets are trading at, or around, 52-week lows. That suggests those in the know believe their company is trading at attractive prices. So much so, t... |
Motley Fool | SPL | 1 year ago |
Starpharma (ASX:SPL) spends September quarter progressing DEP technology
Starpharma (SPL) spent the September quarter progressing its DEP technology and signing a new research agreementIn mid-August, the company signed a new DEP research agreement with MSD to design and synthesise a number of DEP dendrimer conju... |
themarketherald.com.au | SPL | 1 year ago |
Starpharma (ASX:SPL) signs VIRALEZE distribution deal for Hong Kong and Macau
Starpharma (SPL) signs an agreement with Hengan Pharmacare for the sale and distribution of its nasal spray product, VIRALEZE, in Hong Kong and MacauThe agreement will last for an initial two years and will see Starpharma supply VIRALEZE to... |
themarketherald.com.au | SPL | 1 year ago |